Acumen Pharmaceuticals Shares Plunge Following Failed Alzheimer's Clinical Trial
Shares of Acumen Pharmaceuticals (ABOS) experienced a massive decline of over 80% in premarket trading on Friday. The sell-off follows the company's announcement that its mid-stage ALTITUDE-AD clinical trial for the lead drug candidate, sabirnetug, failed to meet both its primary and key secondary endpoints in patients suffering from Alzheimer’s disease. The failure of this pivotal study represents a significant setback for the company's pipeline. As sabirnetug was Acumen's primary focus for treating Alzheimer's, the clinical results have severely impacted investor confidence regarding the firm's near-term development prospects and market valuation.
Tickers: $ABOS
Topics: Alzheimer's disease clinical trial failure drug development stock price crash
Read the full article at Seeking Alpha
Part of the story Geron Corporation Shares Plunge Following Decision to Halt Imetelstat Clinical Trial (2 articles)